[
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ftc-claims-win-teva-moves-delist-hundreds-patents-fda-orange-book\" hreflang=\"en\">FTC claims a win as Teva moves to delist hundreds of patents from FDA Orange Book, agency says</a>",
    "summary": "```json\n{\n  \"summary\": \"The FTC announced that Teva Pharmaceutical has agreed to delist hundreds of patents from the FDA's Orange Book following regulatory pressure. The patents cover products treatin",
    "url": "https://www.fiercepharma.com/pharma/ftc-claims-win-teva-moves-delist-hundreds-patents-fda-orange-book",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cdmo-adare-plots-137-layoffs-philly-shortly-after-transplanting-headquarters-new\" hreflang=\"en\">CDMO Adare plots 137 layoffs in Philly shortly after transplanting headquarters from N.J.</a>",
    "summary": "```json\n{\n  \"summary\": \"CDMO Adare Pharma Solutions is planning to lay off 137 employees at a Philadelphia facility, approximately 18 months after announcing plans to relocate its headquarters from Ne",
    "url": "https://www.fiercepharma.com/manufacturing/cdmo-adare-plots-137-layoffs-philly-shortly-after-transplanting-headquarters-new",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/az-gilead-backed-program-reduced-side-effects-distress-black-breast-cancer-patients-study\" hreflang=\"en\">AZ-, Gilead-backed program reduced side effects, distress in Black breast cancer patients: study</a>",
    "summary": "```json\n{\n  \"summary\": \"A program called 'Care for HER' backed by AstraZeneca and Gilead has demonstrated positive results in reducing side effects and distress among Black breast cancer patients. The",
    "url": "https://www.fiercepharma.com/marketing/az-gilead-backed-program-reduced-side-effects-distress-black-breast-cancer-patients-study",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/fda-awards-1st-national-priority-nod-usantibiotics-augmentin-xr-after-2-month-review\" hreflang=\"en\">FDA awards 1st national priority nod to USAntibiotics' Augmentin XR</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved the first drug under its new Commissioner's National Priority Voucher pilot review program, approximately six months after introducing the pathway. USAntib",
    "url": "https://www.fiercepharma.com/manufacturing/fda-awards-1st-national-priority-nod-usantibiotics-augmentin-xr-after-2-month-review",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/uk-cuts-medicine-discount-rate-us-intervention\" hreflang=\"en\">In win for pharma, UK cuts medicine rebate rate following US intervention</a>",
    "summary": "```json\n{\n  \"summary\": \"The U.K. has reduced the rebate rate that pharmaceutical companies must pay under its cost-control scheme, following a recent trade deal with the U.S. This change will increase",
    "url": "https://www.fiercepharma.com/pharma/uk-cuts-medicine-discount-rate-us-intervention",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/fda-finalizes-guidance-promotional-materials-biologics-and-biosimilars\" hreflang=\"en\">FDA finalizes guidance on promotional materials for biologics and biosimilars</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has issued final guidance this week providing recommendations for manufacturers of prescription biologics and biosimilars on how to approach promotional advertising and",
    "url": "https://www.fiercepharma.com/marketing/fda-finalizes-guidance-promotional-materials-biologics-and-biosimilars",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/italian-non-profit-fondazione-telethon-lands-fda-approval-first-gene-therapy-treat-rare\" hreflang=\"en\">Italian nonprofit lands FDA approval for first gene therapy to treat rare genetic disease</a>",
    "summary": "```json\n{\n  \"summary\": \"Italian nonprofit Fondazione Telethon received FDA approval for Waskyra, the first gene therapy to treat Wiskott-Aldrich syndrome. Waskyra is an ex vivo gene therapy designed t",
    "url": "https://www.fiercepharma.com/pharma/italian-non-profit-fondazione-telethon-lands-fda-approval-first-gene-therapy-treat-rare",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/after-deal-spree-supreme-group-unites-agencies-form-pr-and-communications-group\" hreflang=\"en\">After deal spree, Supreme Group unites agencies to form new PR and communications group</a>",
    "summary": "```json\n{\n  \"summary\": \"Supreme Group has consolidated two of its recently acquired companies, Amendola Communications and Health+Commerce, to form a new PR and communications agency. This consolidati",
    "url": "https://www.fiercepharma.com/marketing/after-deal-spree-supreme-group-unites-agencies-form-pr-and-communications-group",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/pfizer-tukysa-delays-her2-breast-cancer-progression-first-line-maintenance-therapy\" hreflang=\"en\">Pfizer's Tukysa delays HER2 breast cancer progression as 1st-line maintenance therapy</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer has released detailed trial data showing that Tukysa can delay disease progression in HER2-positive breast cancer when used as first-line maintenance therapy. The data s",
    "url": "https://www.fiercepharma.com/pharma/pfizer-tukysa-delays-her2-breast-cancer-progression-first-line-maintenance-therapy",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cdmos-bora-corealis-link-provide-one-stop-shop-oral-solid-dose-production-development\" hreflang=\"en\">CDMOs Bora, Corealis link up to provide one-stop shop for oral solid dose production, development</a>",
    "summary": "```json\n{\n  \"summary\": \"CDMOs Bora and Corealis have formed a strategic alliance to create an integrated end-to-end service offering for oral solid dose drug development and production. The partnershi",
    "url": "https://www.fiercepharma.com/manufacturing/cdmos-bora-corealis-link-provide-one-stop-shop-oral-solid-dose-production-development",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/genentech-uncovers-hidden-gems-latest-iteration-multiple-sclerosis-visibility-drive\" hreflang=\"en\">Genentech uncovers 'Hidden GeMS' in latest iteration of multiple sclerosis visibility drive</a>",
    "summary": "```json\n{\n  \"summary\": \"Genentech has launched a new edition of its long-running awareness campaign called 'Hidden GeMS' focused on multiple sclerosis. The campaign aims to highlight the talents and p",
    "url": "https://www.fiercepharma.com/marketing/genentech-uncovers-hidden-gems-latest-iteration-multiple-sclerosis-visibility-drive",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/roll-tide-lilly-selects-alabama-site-location-6b-api-facility-0\" hreflang=\"en\">Roll Tide: Lilly selects Alabama site as location for $6B API facility</a>",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly has announced Huntsville, Alabama as the location for its $6 billion manufacturing facility, which will be the third of four planned large-scale U.S. plants. The faci",
    "url": "https://www.fiercepharma.com/pharma/roll-tide-lilly-selects-alabama-site-location-6b-api-facility-0",
    "date": "2025-12-11",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/viatris-returns-stake-biocon-biologics-815m-setting-biosimilar-market-re-entry-biocon\" hreflang=\"en\">Biocon buys out Viatris and others from biosimilar subsidiary</a>",
    "summary": "```json\n{\n  \"summary\": \"Biocon is buying back Viatris' stake in Biocon Biologics for $815 million, along with stakes from other investors. This transaction allows Viatris to re-enter the biosimilar ma",
    "url": "https://www.fiercepharma.com/pharma/viatris-returns-stake-biocon-biologics-815m-setting-biosimilar-market-re-entry-biocon",
    "date": "2025-12-11",
    "companies_detected": [
      "Biocon"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-now-has-merck-az-and-sanofi-rsv-shots-infants-its-crosshairs-reuters\" hreflang=\"en\">FDA now has Merck, AZ and Sanofi RSV shots for infants in its crosshairs: Reuters</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA is investigating the safety of RSV shots for infants manufactured by Merck, AstraZeneca, and Sanofi, according to Reuters. This examination comes amid broader vaccine s",
    "url": "https://www.fiercepharma.com/pharma/fda-now-has-merck-az-and-sanofi-rsv-shots-infants-its-crosshairs-reuters",
    "date": "2025-12-11",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma\" hreflang=\"en\">Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in '26</a>",
    "summary": "```json\n{\n  \"summary\": \"The Senate and House released the final text of the National Defense Authorization Act for fiscal year 2026, which includes language from the Biosecure Act. This legislation wo",
    "url": "https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/eye-ai-imre-hires-nadine-lafond-ogilvy-fill-ceo-vacancy\" hreflang=\"en\">With eye on AI, Imre hires Nadine Lafond from Ogilvy Health to fill CEO vacancy</a>",
    "summary": "```json\n{\n  \"summary\": \"Ad agency Imre has appointed Nadine Lafond from Ogilvy Health as its new CEO. The hire comes as the company focuses on artificial intelligence capabilities. Lafond is moving fr",
    "url": "https://www.fiercepharma.com/marketing/eye-ai-imre-hires-nadine-lafond-ogilvy-fill-ceo-vacancy",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/its-future-still-limbo-csl-seqirus-debuts-1b-flu-shot-antivenom-plant-australia\" hreflang=\"en\">Its future still in limbo, CSL Seqirus debuts $1B flu shot, antivenom plant in Australia</a>",
    "summary": "```json\n{\n  \"summary\": \"CSL has opened a new $1 billion manufacturing facility in Melbourne, Australia for its Seqirus vaccine division, producing cell-based flu shots and antivenom products. This dev",
    "url": "https://www.fiercepharma.com/manufacturing/its-future-still-limbo-csl-seqirus-debuts-1b-flu-shot-antivenom-plant-australia",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/once-public-now-private-gamida-cell-scores-2nd-fda-nod-stem-cell-therapy-omisirge\" hreflang=\"en\">Once public, now private, Gamida Cell scores 2nd FDA nod for stem cell therapy Omisirge</a>",
    "summary": "```json\n{\n  \"summary\": \"Gamida Cell, now a private company after previously being public, has received FDA approval to expand the use of its cell therapy Omisirge for treating severe aplastic anemia. ",
    "url": "https://www.fiercepharma.com/pharma/once-public-now-private-gamida-cell-scores-2nd-fda-nod-stem-cell-therapy-omisirge",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma\" hreflang=\"en\">ASH: J&amp;J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Johnson & Johnson presented positive trial data at ASH for a combination therapy involving Tecvayli, a bispecific antibody for multiple myeloma. The data suggests this combinat",
    "url": "https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/lilly-oncology-chief-sees-jaypirca-sweet-spot-second-line-cll-despite-first-line-btk-trial\" hreflang=\"en\">ASH: Lilly oncology chief sees sweet spot for Jaypirca in 2nd-line CLL despite 1st-line trial wins</a>",
    "summary": "```json\n{\n  \"summary\": \"Lilly's oncology chief Jacob Van Naarden stated that despite positive phase 3 data supporting first-line approval of BTK inhibitor Jaypirca in chronic lymphocytic leukemia (CLL",
    "url": "https://www.fiercepharma.com/pharma/lilly-oncology-chief-sees-jaypirca-sweet-spot-second-line-cll-despite-first-line-btk-trial",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/pfizer-lilly-jj-and-more-see-inclusions-chinas-first-batch-picks-new-private-insurance\" hreflang=\"en\">Meds from Pfizer, Lilly, J&amp;J and more secure spots in China's 1st private insurance formulary</a>",
    "summary": "```json\n{\n  \"summary\": \"China's National Healthcare Security Administration announced its first batch of 19 medications selected for the new Commercial Health Insurance Innovative Drug Catalogue. The ",
    "url": "https://www.fiercepharma.com/pharma/pfizer-lilly-jj-and-more-see-inclusions-chinas-first-batch-picks-new-private-insurance",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fast-rising-ucb-set-file-approval-fintepla-3rd-epileptic-disorder\" hreflang=\"en\">Fast-rising UCB set to file for Fintepla approval in 3rd epileptic disorder after trial win</a>",
    "summary": "```json\n{\n  \"summary\": \"UCB announced plans to file for regulatory approval of Fintepla for a third epileptic condition following positive phase 3 trial results in patients with CDKL5 deficiency disor",
    "url": "https://www.fiercepharma.com/pharma/fast-rising-ucb-set-file-approval-fintepla-3rd-epileptic-disorder",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/amgen-inks-la-sports-entertainment-partnership-setting-2026-world-cup-presence\" hreflang=\"en\">Amgen inks LA sports, entertainment partnership, setting up 2026 World Cup presence</a>",
    "summary": "```json\n{\n  \"summary\": \"Amgen has announced a new sports and entertainment partnership in Greater Los Angeles, its hometown area. The partnership is designed to increase the company's profile and incl",
    "url": "https://www.fiercepharma.com/marketing/amgen-inks-la-sports-entertainment-partnership-setting-2026-world-cup-presence",
    "date": "2025-12-11",
    "companies_detected": [
      "Amgen"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025\" hreflang=\"en\">Regulatory tracker: Agios awaits FDA decision as target date passes</a>",
    "summary": "```json\n{\n  \"summary\": \"Fierce Pharma is maintaining a regulatory tracker to monitor the progress of in-market pharmaceutical products, including geographic expansions and new indication approvals. Th",
    "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine\" hreflang=\"en\">Beyond the treatment: Innovation on the human side of medicine</a>",
    "summary": "```json\n{\n  \"summary\": \"This article discusses how a pharmaceutical company's focus on understanding the patient journey is driving innovation to make healthcare more intuitive and equitable. The piec",
    "url": "https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "summary": "```json\n{\n  \"summary\": \"Medincell has published its consolidated half-year financial results covering the period from April 1st, 2025 to September 30, 2025. This announcement provides stakeholders wit",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "summary": "```json\n{\n  \"summary\": \"Teva Pharmaceuticals, in partnership with MedinCell, has submitted a New Drug Application (NDA) to the U.S. FDA for TEV-'749/mdc-TJK, an olanzapine extended-release injectable ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Videoconference and publication of half-year financial results, Tuesday, December 9, 2025",
    "summary": "```json\n{\n  \"summary\": \"A videoconference is scheduled for Tuesday, December 9, 2025, to announce and discuss half-year financial results. This appears to be a corporate financial reporting event, tho",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_ConfHYR_01122025_EN.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference",
    "summary": "```json\n{\n  \"summary\": \"MedinCell management will present at two upcoming healthcare conferences: the 8th Annual Evercore Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference.",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Evercore-Piper_Sandler_EN_27112025.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "summary": "```json\n{\n  \"summary\": \"MedinCell has been awarded a new grant to support its efforts in fighting malaria. This funding will help advance the company's work in developing treatments or preventive ther",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "[Replay] Jefferies Global Healthcare Conference 2025",
    "summary": "```json\n{\n  \"summary\": \"This appears to be an announcement of a replay or recording availability for the Jefferies Global Healthcare Conference 2025. The text does not provide specific details about p",
    "url": "https://wsw.com/webcast/jeff332/medcl/1970687",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "summary": "```json\n{\n  \"summary\": \"Medincell has appointed Dr. Grace Kim as Chief Strategy Officer for U.S. Finance to support the company's next phase of capital growth in the United States. This corporate lead",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "summary": "```json\n{\n  \"summary\": \"MedinCell has been selected to join the MSCI World Small Cap Index, a prominent global equity benchmark. This inclusion represents a significant corporate milestone for the bio",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)",
    "summary": "```json\n{\n  \"summary\": \"Medincell announced its participation in two upcoming healthcare investor conferences: the UBS Global Healthcare Conference in Palm Beach and the Stifel Healthcare Conference i",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_UBS-STIFEL_06112025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "summary": "```json\n{\n  \"summary\": \"Teva's UZEDY® (risperidone extended-release injectable suspension) continues to demonstrate strong commercial growth. The company is preparing to submit a New Drug Application ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)",
    "summary": "```json\n{\n  \"summary\": \"MedinCell announced its participation in the 2025 Truist Securities Biopharma Symposium taking place in New York. This is a corporate event where the company will likely presen",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_Truist_22102025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved an expanded indication for UZEDY® (risperidone) extended-release injectable suspension for the treatment of adults with Bipolar I Disorder. This represents",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [
      "risperidone"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-approves-its-1st-non-drug-home-treatment-depression-flow-neurosciences-brain-headset\" hreflang=\"en\">FDA approves 1st nondrug, at-home treatment for depression</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved Flow Neuroscience's brain headset as the first non-drug, at-home treatment for depression. The wearable device can be used as a standalone treatment or in ",
    "url": "https://www.fiercebiotech.com/medtech/fda-approves-its-1st-non-drug-home-treatment-depression-flow-neurosciences-brain-headset",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/zealand-pens-25b-cardiometabolic-collab-fresh-faced-chinese-biotech\" hreflang=\"en\">Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech</a>",
    "summary": "```json\n{\n  \"summary\": \"Zealand Pharma has entered into a cardiometabolic collaboration with Chinese biotech OTR, worth up to $2.5 billion in total deal value. The agreement includes $30 million in up",
    "url": "https://www.fiercebiotech.com/biotech/zealand-pens-25b-cardiometabolic-collab-fresh-faced-chinese-biotech",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gri-touts-ipf-safety-edge-lung-function-gains-amid-cash-crunch\" hreflang=\"en\">GRI touts IPF safety edge, lung function gains amid cash crunch</a>",
    "summary": "```json\n{\n  \"summary\": \"GRI Bio has released phase 2a clinical trial data for its potentially disease-modifying therapy in idiopathic pulmonary fibrosis (IPF), highlighting safety advantages and lung ",
    "url": "https://www.fiercebiotech.com/biotech/gri-touts-ipf-safety-edge-lung-function-gains-amid-cash-crunch",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/apple-tree-partners-files-chapter-11-bankruptcy-keep-cash-flowing-portfolio-biotechs\" hreflang=\"en\">Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs</a>",
    "summary": "```json\n{\n  \"summary\": \"Two affiliates of Apple Tree Partners have filed for Chapter 11 bankruptcy as a strategic move to maintain funding for their portfolio biotechnology companies. The bankruptcy f",
    "url": "https://www.fiercebiotech.com/biotech/apple-tree-partners-files-chapter-11-bankruptcy-keep-cash-flowing-portfolio-biotechs",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/sanofi-gsk-ink-preclinical-pacts-quest-new-autoimmune-and-cancer-antibodies\" hreflang=\"en\">Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies</a>",
    "summary": "```json\n{\n  \"summary\": \"Sanofi and GSK have each established new preclinical research partnerships to advance their drug discovery efforts. Sanofi is investing in a U.S. biotech company focused on aut",
    "url": "https://www.fiercebiotech.com/biotech/sanofi-gsk-ink-preclinical-pacts-quest-new-autoimmune-and-cancer-antibodies",
    "date": "2025-12-11",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/bleekers-big-bang-formation-bio-unveils-new-subsidiary-605m-lynk-deal\" hreflang=\"en\">Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal </a>",
    "summary": "```json\n{\n  \"summary\": \"Formation Bio is acquiring ex-China rights to a next-generation immunology asset from Lynk Pharmaceuticals in a deal valued at over $605 million in biobucks. The transaction in",
    "url": "https://www.fiercebiotech.com/biotech/bleekers-big-bang-formation-bio-unveils-new-subsidiary-605m-lynk-deal",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/francis-medical-gets-fda-green-light-water-vapor-ablation-therapy-treat-prostate-cancer\" hreflang=\"en\">Francis Medical gets FDA green light for water vapor ablation to treat prostate cancer</a>",
    "summary": "```json\n{\n  \"summary\": \"Francis Medical received FDA 510(k) clearance for its water vapor ablation therapy to treat cancers of the prostate, kidneys, and bladder. This regulatory approval allows the c",
    "url": "https://www.fiercebiotech.com/medtech/francis-medical-gets-fda-green-light-water-vapor-ablation-therapy-treat-prostate-cancer",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/roche-links-oral-serd-30-breast-cancer-risk-reduction-phase-3-adjuvant-trial\" hreflang=\"en\">Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial</a>",
    "summary": "```json\n{\n  \"summary\": \"Roche announced positive phase 3 results for giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrating a 30% reduction in the risk of invasive disease re",
    "url": "https://www.fiercebiotech.com/biotech/roche-links-oral-serd-30-breast-cancer-risk-reduction-phase-3-adjuvant-trial",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25\" hreflang=\"en\">Fierce Biotech Fundraising Tracker '25: D3 Bio raises $108M; BlossomHill grows $84M</a>",
    "summary": "```json\n{\n  \"summary\": \"Fierce Biotech's 2025 fundraising tracker reports two significant venture capital rounds. D3 Bio secured $108 million and BlossomHill raised $84 million, both exceeding the tra",
    "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chinese-biotech-helmed-az-veteran-reels-108-series-b-kras-inhibitor-phase-3-plans\" hreflang=\"en\">Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans</a>",
    "summary": "```json\n{\n  \"summary\": \"A Chinese biotech company led by a former AstraZeneca executive has raised $108 million in Series B financing. The funds will be used to advance the company's lead KRAS inhibit",
    "url": "https://www.fiercebiotech.com/biotech/chinese-biotech-helmed-az-veteran-reels-108-series-b-kras-inhibitor-phase-3-plans",
    "date": "2025-12-11",
    "companies_detected": [
      "AstraZeneca"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/strong-words-big-smiles-enduring-activism-and-cautious-optimism-american-society-hematology\" hreflang=\"en\">Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025</a>",
    "summary": "```json\n{\n  \"summary\": \"This article discusses the atmosphere and themes at the American Society of Hematology (ASH) 2025 conference held in Orlando. The piece focuses on the mood of 'enduring activis",
    "url": "https://www.fiercebiotech.com/biotech/strong-words-big-smiles-enduring-activism-and-cautious-optimism-american-society-hematology",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/teleflex-inks-2b-divestment-deals-oem-urology-and-acute-care-units\" hreflang=\"en\">Teleflex inks $2B in divestment deals for OEM, urology and acute care units</a>",
    "summary": "```json\n{\n  \"summary\": \"Teleflex is divesting three business units in deals totaling approximately $2 billion. Private equity firms Montagu and Kohlberg are acquiring the OEM division for $1.5 billion",
    "url": "https://www.fiercebiotech.com/medtech/teleflex-inks-2b-divestment-deals-oem-urology-and-acute-care-units",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/cro/fda-clears-1st-ai-drug-development-tool-reading-mash-images\" hreflang=\"en\">FDA qualifies 1st AI drug development tool for reading MASH images</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has qualified its first artificial intelligence tool designed to assist drug developers in evaluating fatty liver disease during clinical trials. This AI-based tool wil",
    "url": "https://www.fiercebiotech.com/cro/fda-clears-1st-ai-drug-development-tool-reading-mash-images",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/medline-sets-terms-massive-537b-nasdaq-ipo\" hreflang=\"en\">Medline sets terms for massive $5.37B Nasdaq IPO</a>",
    "summary": "```json\n{\n  \"summary\": \"Medline, a medical device manufacturing and distribution giant, has set terms for a massive $5.37 billion IPO on Nasdaq. The company could achieve a valuation of approximately ",
    "url": "https://www.fiercebiotech.com/medtech/medline-sets-terms-massive-537b-nasdaq-ipo",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-exicure-rebounds-phase-2-win-90-blood-cell-mobilization-myeloma\" hreflang=\"en\">ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Exicure reported positive phase 2 results for its investigational small molecule in multiple myeloma, achieving approximately 90% mobilization of blood-forming cells. This succ",
    "url": "https://www.fiercebiotech.com/biotech/ash-exicure-rebounds-phase-2-win-90-blood-cell-mobilization-myeloma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ose-narrows-focus-conserve-cash-expense-wider-pipeline\" hreflang=\"en\">Ose narrows focus to conserve cash at expense of wider pipeline</a>",
    "summary": "```json\n{\n  \"summary\": \"Ose Immunotherapeutics is implementing a strategic refocusing to conserve cash by narrowing its pipeline priorities. The company will concentrate its resources on two key progr",
    "url": "https://www.fiercebiotech.com/biotech/ose-narrows-focus-conserve-cash-expense-wider-pipeline",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug\" hreflang=\"en\">Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer has entered into a $1.9 billion biobucks deal with a Fosun unit, paying $150 million upfront for a GLP-1 drug candidate. This partnership represents Pfizer's continued p",
    "url": "https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease\" hreflang=\"en\">ASH: Novartis details ianalumab's phase 3 win in rare blood disease</a>",
    "summary": "```json\n{\n  \"summary\": \"Novartis presented detailed phase 3 results for ianalumab at ASH (American Society of Hematology) meeting, showing positive outcomes in treating a rare autoimmune blood disorde",
    "url": "https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease",
    "date": "2025-12-11",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma\" hreflang=\"en\">ASH: J&amp;J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Johnson & Johnson presented positive trial data at ASH for a combination therapy involving Tecvayli, a bispecific antibody for multiple myeloma. The data suggests this combinat",
    "url": "https://www.fiercebiotech.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs\" hreflang=\"en\">GSK cuts the cord on Ideaya collaboration, letting go of 2 programs</a>",
    "summary": "```json\n{\n  \"summary\": \"GSK is terminating its five-year collaboration with Ideaya Biosciences, relinquishing rights to two programs. The partnership originally focused on three of Ideaya's synthetic ",
    "url": "https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-policy-shift\" hreflang=\"en\">FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA is implementing a policy shift requiring CAR T-cell therapy developers in oncology to demonstrate superiority over existing treatments through randomized trials. This r",
    "url": "https://www.fiercebiotech.com/biotech/fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-policy-shift",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech\" hreflang=\"en\">Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech</a>",
    "summary": "```json\n{\n  \"summary\": \"Novartis has entered into a $1.7 billion biobucks partnership with a British AI-enabled biotech company to discover new targets for immuno-dermatology conditions. The deal leve",
    "url": "https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech",
    "date": "2025-12-11",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-merck-mulls-future-polycythemia-program-while-takeda-takes-ph-3-victory-lap\" hreflang=\"en\">ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap</a>",
    "summary": "```json\n{\n  \"summary\": \"Merck & Co. and Takeda presented new data on their polycythemia vera programs at the American Society of Hematology conference in Orlando, Florida. Polycythemia vera is a rare ",
    "url": "https://www.fiercebiotech.com/biotech/ash-merck-mulls-future-polycythemia-program-while-takeda-takes-ph-3-victory-lap",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation\" hreflang=\"en\">With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec</a>",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly, with its best-selling medication tirzepatide and a record $1 trillion valuation, is planning to leverage its significant financial windfall from weight loss drugs to",
    "url": "https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation",
    "date": "2025-12-11",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-clears-resmed-ai-personalizing-cpap-settings\" hreflang=\"en\">FDA clears Resmed AI for personalizing CPAP settings</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has granted clearance to ResMed's artificial intelligence-powered system for personalizing CPAP machine settings. The AI-enabled approach is designed to optimize therap",
    "url": "https://www.fiercebiotech.com/medtech/fda-clears-resmed-ai-personalizing-cpap-settings",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "House backs Biosecure Act aimed at Chinese companies",
    "summary": "```json\n{\n  \"summary\": \"The U.S. House of Representatives approved a defense bill that includes a diluted version of the Biosecure Act. The legislation aims to restrict federal contracts with certain ",
    "url": "https://endpoints.news/house-backs-biosecure-act-aimed-at-chinese-companies/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Investors buy up stocks in biggest follow-on offering day in biotech history",
    "summary": "```json\n{\n  \"summary\": \"A record-breaking $3.2 billion in biotech follow-on stock offerings were sold within a 24-hour period, marking the biggest follow-on offering day in biotech history. Eight biot",
    "url": "https://endpoints.news/investors-buy-up-stocks-in-biggest-follow-on-offering-day-in-biotech-history/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Apple Tree files for bankruptcy as it seeks funds from Russian billionaire backer",
    "summary": "```json\n{\n  \"summary\": \"Apple Tree Partners, a venture capital firm, has filed for voluntary Chapter 11 bankruptcy protection in US bankruptcy court. The firm is seeking to restructure its operations ",
    "url": "https://endpoints.news/apple-tree-files-for-bankruptcy-as-it-seeks-funds-from-russian-billionaire-backer/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "USAntibiotics scores sped-up approval for amoxicillin",
    "summary": "```json\n{\n  \"summary\": \"USAntibiotics received FDA approval for its American-made extended-release amoxicillin approximately two months ahead of the standard timeline. This marks the first product app",
    "url": "https://endpoints.news/usantibiotics-scores-sped-up-approval-for-amoxicillin/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Adare Pharma shutters Philadelphia site and lays off over 100 staffers",
    "summary": "```json\n{\n  \"summary\": \"Adare Pharma Solutions, a CDMO, is closing its 128,000 square foot Philadelphia facility and laying off 137 employees. This closure comes approximately one year after the compa",
    "url": "https://endpoints.news/adare-pharma-shutters-philadelphia-site-and-lays-off-over-100-staffers/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "In a first, FDA approves a gene therapy from a nonprofit",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved Waskyra, a gene therapy for Wiskott-Aldrich syndrome, marking the first gene therapy approval from a nonprofit organization. This treatment provides a new ",
    "url": "https://endpoints.news/in-a-first-fda-approves-a-gene-therapy-from-a-nonprofit/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "J&J joins 'menin party' at ASH; GSK to work with Oxford BioTherapeutics",
    "summary": "```json\n{\n  \"summary\": \"Johnson & Johnson presented data on its menin inhibitor at the ASH conference, joining Kura and Syndax in this therapeutic area. The news roundup also mentions GSK partnering w",
    "url": "https://endpoints.news/j-gsk-to-work-with-oxford-biotherapeutics/",
    "date": "2025-12-10",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%",
    "summary": "```json\n{\n  \"summary\": \"Roche presented interim data at SABCS25 showing that their experimental breast cancer pill reduced the risk of invasive disease recurrence by 30% in patients treated directly a",
    "url": "https://endpoints.news/sabcs25-roches-breast-cancer-pill-cuts-post-surgery-disease-recurrence-risk-by-30/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "PsiThera gets $47.5M for oral I&I drugs after spinning out from Roivant",
    "summary": "```json\n{\n  \"summary\": \"PsiThera, a biotech company spun out from Roivant, has raised $47.5 million in Series A funding. The company is developing an oral drug targeting the same mechanism as Humira (",
    "url": "https://endpoints.news/psithera-gets-47-5m-for-oral-ii-drugs-after-spinning-out-from-roivant/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Formation Bio signs deal for TYK2 drug from China's Lynk",
    "summary": "```json\n{\n  \"summary\": \"Formation Bio has signed a deal to acquire a TYK2 inhibitor drug from China-based Lynk Pharmaceuticals. TYK2 has emerged as a highly sought-after target in immunology since Tak",
    "url": "https://endpoints.news/formation-bio-signs-deal-for-tyk2-drug-from-chinas-lynk/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "UK lowers new medicine rebate scheme to 14.5% for 2026",
    "summary": "```json\n{\n  \"summary\": \"The UK government will reduce its drug rebate tax on new medicines to 14.5% for 2026, down from nearly 23%. This change follows the recently announced UK-US trade deal.\",\n  \"ev",
    "url": "https://endpoints.news/uk-lowers-new-medicine-rebate-scheme-to-14-5-for-2026/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3",
    "summary": "```json\n{\n  \"summary\": \"D3 Bio, a Shanghai-based biotech company, has raised $108 million in Series B funding. The primary objective is to advance its lead drug candidate targeting KRAS G12C into glob",
    "url": "https://endpoints.news/d3-bio-raises-108m-to-take-next-gen-kras-g12c-drug-into-phase-3/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "BlossomHill gets another $84M for macrocyclic approach to EGFR",
    "summary": "```json\n{\n  \"summary\": \"BlossomHill Therapeutics, a San Diego-based biotech startup, has raised $84 million in additional funding to advance its macrocyclic approach targeting EGFR. The company has tw",
    "url": "https://endpoints.news/blossomhill-gets-another-84m-for-macrocyclic-approach-to-egfr/",
    "date": "2025-12-10",
    "companies_detected": [
      "AstraZeneca"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "FDA is taking another look at safety of approved RSV antibodies",
    "summary": "```json\n{\n  \"summary\": \"The FDA is conducting a safety review of two approved RSV antibodies used for infants. The agency has contacted drugmakers regarding this reexamination, which is part of broade",
    "url": "https://endpoints.news/fda-is-taking-another-look-at-safety-of-approved-rsv-antibodies/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Eli Lilly earmarks $6B for GLP-1 pill factory in Alabama",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly is investing $6 billion to construct a manufacturing facility in Huntsville, Alabama dedicated to producing orforglipron, an oral GLP-1 medication. This represents th",
    "url": "https://endpoints.news/eli-lilly-earmarks-6b-for-glp-1-pill-factory-in-alabama/",
    "date": "2025-12-09",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "FDA's probe of Covid-19 vaccines expands into adults",
    "summary": "```json\n{\n  \"summary\": \"The FDA has expanded its investigation of Covid-19 vaccine safety from children to include adults, representing a significant broadening of the agency's probe. This expansion c",
    "url": "https://endpoints.news/fdas-probe-of-covid-19-vaccines-expands-into-adults/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: New data from Gilead, J&J set up a bispecific, CAR-T rivalry",
    "summary": "```json\n{\n  \"summary\": \"At the American Society of Hematology's annual meeting in Orlando, Johnson & Johnson, Gilead, and Arcellx presented new clinical trial data in multiple myeloma, highlighting a ",
    "url": "https://endpoints.news/ash25-new-data-from-gilead-jj-set-up-a-bispecific-car-t-rivalry/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "J&J-backed Cellular Origins raises $40M for cell therapy manufacturing",
    "summary": "```json\n{\n  \"summary\": \"UK-based cell therapy manufacturer Cellular Origins has raised $40 million in an over-subscribed Series A funding round led by Johnson & Johnson's venture capital arm. The comp",
    "url": "https://endpoints.news/jj-backed-cellular-origins-raises-40m-for-cell-therapy-manufacturing/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "SanegeneBio raises $110M in follow-up to metabolic deal with Lilly",
    "summary": "```json\n{\n  \"summary\": \"SanegeneBio has raised $110 million in a Series B financing round, coming just one month after announcing a partnership with Eli Lilly focused on developing RNAi drugs for meta",
    "url": "https://endpoints.news/chinas-sanegenebio-raises-110m-in-follow-up-to-metabolic-deal-with-lilly/",
    "date": "2025-12-09",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Novartis to partner with AI-focused Relation on atopic diseases",
    "summary": "```json\n{\n  \"summary\": \"Novartis has entered into a partnership with UK-based biotech company Relation to discover and develop new drugs for certain immune diseases, specifically atopic diseases. This",
    "url": "https://endpoints.news/novartis-to-partner-with-relation-therapeutics-on-atopic-diseases/",
    "date": "2025-12-09",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Notes from the 2025 SABEW med tech fellowship",
    "summary": "```json\n{\n  \"summary\": \"The text discusses observations from the 2025 SABEW med tech fellowship regarding increased attention to wearable devices. HHS Secretary Robert F. Kennedy Jr. is promoting wide",
    "url": "https://endpoints.news/notes-from-the-2025-sabew-med-tech-fellowship/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: Early in vivo CAR-T results like Kelonia's elicit excitement across the field",
    "summary": "```json\n{\n  \"summary\": \"Kelonia Therapeutics reported early clinical trial results at ASH25 showing that a single infusion of their ready-made CAR-T therapy eliminated detectable cancer cells in four ",
    "url": "https://endpoints.news/ash25-early-in-vivo-car-t-results-like-kelonias-elicit-excitement-across-the-field/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "EpilepsyGTx gets $33M to test epilepsy gene therapy in Phase 1/2a",
    "summary": "```json\n{\n  \"summary\": \"EpilepsyGTx, a London-based biotech startup with two employees, has secured $33 million in Series A funding after over two years of fundraising efforts. The funding will be use",
    "url": "https://endpoints.news/epilepsygtx-gets-33m-to-test-epilepsy-gene-therapy-in-phase-1-2a/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Stealthy biotech Sidera Bio raises $109M; Assembly's data for oral herpes drugs",
    "summary": "```json\n{\n  \"summary\": \"Sidera Bio, a stealthy biotech company, has raised $109 million in Series funding from investors including Novo Holdings, Forbion, RA Capital Healthcare Fund, and Gilde Healthc",
    "url": "https://endpoints.news/stealthy-biotech-sidera-bio-raises-109m-assemblys-data-for-oral-herpes-drugs/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech Seeks an Experienced Quality Director",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech is recruiting for an Experienced Quality Director position. This is a corporate hiring announcement with no specific details about drug development programs or partne",
    "url": "https://www.delsitech.com/delsitech-seeks-an-experienced-quality-director/",
    "date": "2025-12-11",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech is Hiring a Process Engineer",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech is recruiting for a Process Engineer position. This is a corporate hiring announcement with no specific details about drug development programs or partnerships.\",\n  \"",
    "url": "https://www.delsitech.com/delsitech-is-hiring-a-process-engineer/",
    "date": "2025-12-11",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech announces a leadership change. Carl-Åke Carlsson, CEO of DelSiTech, leaves the company and the Board nominates Martti Hedman as Interim CEO.",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech announces a leadership transition with CEO Carl-Åke Carlsson departing the company. The Board has appointed Martti Hedman to serve as Interim CEO following Carlsson's",
    "url": "https://www.delsitech.com/delsitech-announces-a-leadership-change-carl-ake-carlsson-ceo-of-delsitech-leaves-the-company-and-the-board-nominates-martti-hedman-as-interim-ceo/",
    "date": "2025-12-11",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Appointment of Outi Heikkilä as Chief Operations Officer",
    "summary": "```json\n{\n  \"summary\": \"Outi Heikkilä has been appointed as Chief Operations Officer. This is a corporate leadership announcement indicating an executive-level personnel change. No additional details ",
    "url": "https://www.delsitech.com/appointment-of-outi-heikkila-as-chief-operations-officer/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "summary": "```json\n{\n  \"summary\": \"Partnership Opportunities in Drug Delivery 2025 is a conference taking place in Boston on October 27-28. The event focuses on drug delivery partnerships and involves multiple b",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress Europe 2025 Amsterdam, October 13-16",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress Europe 2025 will be held in Amsterdam from October 13-16. This is a conference event focused on vaccine development and related topics in the pharmac",
    "url": "https://www.delsitech.com/world-vaccine-congress-europe-2025-amsterdam-october-13-16/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Drug Delivery and Formulation Summit 2025 Boston, September 15-16",
    "summary": "```json\n{\n  \"summary\": \"The Drug Delivery and Formulation Summit 2025 is scheduled to take place in Boston on September 15-16. This appears to be an industry conference focused on drug delivery techno",
    "url": "https://www.delsitech.com/drug-delivery-and-formulation-summit-2025-boston-september-15-16/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "CRS Annual Meeting & Exposition 2025 Philadelphia, July 14-18",
    "summary": "```json\n{\n  \"summary\": \"The Controlled Release Society (CRS) is hosting its Annual Meeting & Exposition 2025 in Philadelphia from July 14-18. This is a conference announcement for a major industry eve",
    "url": "https://www.delsitech.com/crs-annual-meeting-exposition-2025-philadelphia-july-14-18/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "summary": "```json\n{\n  \"summary\": \"The BIO International Convention 2025 will be held in Boston from June 16-19. This is an announcement of a major industry conference event.\",\n  \"event_type\": \"other\",\n  \"compan",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress 2025 Washington, April 21-24",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress 2025 will be held in Washington from April 21-24. This is a conference event focused on vaccine development and related topics in the pharmaceutical ",
    "url": "https://www.delsitech.com/world-vaccine-congress-2025-washington-april-21-24/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "summary": "```json\n{\n  \"summary\": \"Nanexa and Moderna have entered into a license and option agreement for the development of products based on Nanexa's PharmaShell® technology platform. This partnership will en",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "summary": "```json\n{\n  \"summary\": \"Nanexa and Moderna have entered into a license and option agreement for the development of products based on Nanexa's PharmaShell® technology platform. This partnership will en",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the January-September 2025 period. This is a routine corporate disclosure providing updates on the company's financia",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the January-September 2025 period. This is a routine corporate disclosure providing updates on the company's financia",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "```json\n{\n  \"summary\": \"The provided text contains only 'Download attachment' without any substantive biotech/pharma news content to analyze. No companies, molecules, technologies, or therapeutic indi",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the period from January to June 2025. This is a routine corporate disclosure providing updates on the company's finan",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "```json\n{\n  \"summary\": \"The provided text contains only 'Download attachment' without any substantive biotech/pharma news content to analyze. No companies, molecules, technologies, or therapeutic indi",
    "url": "https://storage.mfn.se/5d2c8421-0163-4592-8c9e-43752659a104/nanexa-interim-report-january-june-2025.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Read the presentation",
    "summary": "```json\n{\n  \"summary\": \"The text provided contains only the phrase 'Read the presentation' without any substantive biotech/pharma news content. No specific companies, molecules, technologies, or thera",
    "url": "https://nanexa.com/wp-content/uploads/2025/11/PODD-Oct-2025.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  }
]